Disturbed Neurotransmitter Transporter Expression in Alzheimer’s Disease Brain
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia. An imbalance of different neurotransmitters--glutamate, acetylcholine, dopamine, and serotonin--has been proposed as the neurobiological basis of behavioral symptoms in AD. The molecular changes associated with neurotransmission imbalance in AD are not clear. We hypothesized that altered reuptake of neurotransmitters by vesicular glutamate transporters (VGLUTs), excitatory amino acid transporters (EAATs), the vesicular acetylcholine transporter (VAChT), the serotonin reuptake transporter (SERT), or the dopamine reuptake transporter (DAT) are involved in the neurotransmission imbalance in AD. We tested this hypothesis by examining protein and mRNA levels of these transporters in postmortem prefrontal cortex from 10 AD patients and 10 matched non-AD controls. Compared with controls, protein and mRNA levels of VGLUTs, EAAT1-3, VAChT, and SERT were reduced significantly in AD. Expression of DAT and catechol O-methyltransferase was unchanged. Reduced VGLUTs and EAATs may contribute to an alteration in glutamatergic recycling, and reduced SERT could exacerbate depressive symptoms in AD. The reduced VAChT expression could contribute to the recognized cholinergic deficit in AD. Altered neurotransmitter transporters could contribute to the pathophysiology of AD and are potential targets for therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061509598 · Cited by 467 · cited 1×
“The prefrontal cortex also was chosen because of reported changes there in blood flow and glucose and arachidonic acid metabolism in living AD patients, and because of the characteristic pathology (senile neuritic plaques and beta amyloid accumulation) observed in post-mortem tissue [33–42].”
Self-citationSerotonin-1A receptor imaging in recurrent depression: replication and literature review
Drevets, W. C., Thase, M. E., Moses-Kolko, E. L., Price, J., Frank, E., Kupfer, D. J., & Mathis, C. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.06.008 · Cited by 399 · cited 1×
“A disturbed serotonergic system is commonly associated with depression and aggression, since it influences mood and feelings of well being [6].”
Astrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain
Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., Savva, G., Brayne, C., & Wharton, S. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.015 · Cited by 381 · cited 1×
“lier reports in AD brain [55–59].”
LI, S., MALLORY, M., ALFORD, M., TANAKA, S., & MASLIAH, E. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00008 · Cited by 343
Harrison, P. J., Heath, P. R., Eastwood, S. L., Burnet, P. W. J., McDonald, B., & Pearson, R. C. A. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12102-a · Cited by 342 · cited 1×
“[44].”
Jacob, C. P., Koutsilieri, E., Bartl, J., Neuen-Jacob, E., Arzberger, T., Zander, N., Ravid, R., Roggendorf, W., Riederer, P., & Grünblatt, E. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11113 · Cited by 317 · cited 1×
“lier reports in AD brain [55–59].”
The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer’s disease.
Reisberg, B., Prichep, L., Mosconi, L., John, E. R., Glodzik‐Sobanska, L., Boksay, I., Monteiro, I., Torossian, C., Vedvyas, A., Ashraf, N., et al. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.11.017 · Cited by 312 · cited 1×
“The AD patients were diagnosed with advanced stages of AD based on neuropathological and behavioral observations [43] and controls are devoid of any psychiatric illnesses.”
The interplay of neurotransmitters in Alzheimer's disease
Francis, P. T. (2005) · CNS Spectrums · doi:10.1017/s1092852900014164 · Cited by 302 · cited 3×
“This may explain the excessive “background signaling” of glutamate proposed for AD [5].”
Prado, V. F., Martins-Silva, C., de Castro, B. M., Lima, R. F., Barros, D. M., Amaral, E., Ramsey, A. J., Sotnikova, T. D., Ramirez, M. R., Kim, H.-G., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.08.005 · Cited by 246
Self-citation
Cited by
Extrasynaptic NMDA Receptor Involvement in Central Nervous System Disorders
Parsons, M. P., & Raymond, L. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.030 · Cited by 553
Isolation of glia from Alzheimer’s mice reveals inflammation and dysfunction
Orre, M., Kamphuis, W., Osborn, L. M., Jansen, A. H. P., Kooijman, L., Bossers, K., & Hol, E. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.004 · Cited by 394
Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients
Rao, J. S., Keleshian, V. L., Klein, S., & Rapoport, S. I. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.55 · Cited by 304
Self-citationDysfunction of NMDA receptors in Alzheimer’s disease
Zhang, Y., Li, P., Feng, J., & Wu, M. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2546-5 · Cited by 282
“The expression of glutamate transporters is reduced significantly both in human tissue from AD patients [54] and animal models of AD [55].”
BackgroundDepression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
Regional protein expression in human Alzheimer’s brain correlates with disease severity
Xu, J., Patassini, S., Rustogi, N., Riba-Garcia, I., Hale, B. D., Phillips, A. M., Waldvogel, H., Haines, R., Bradbury, P., Stevens, A., et al. (2019) · Communications Biology · doi:10.1038/s42003-018-0254-9 · Cited by 181
Altered synapses and gliotransmission in Alzheimer's disease and AD model mice
Mitew, S., Kirkcaldie, M. T. K., Dickson, T. C., & Vickers, J. C. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.010 · Cited by 138
The mechanisms of ferroptosis and its role in alzheimer’s disease
Ma, H., Dong, Y., Chu, Y., Guo, Y., & Li, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.965064 · Cited by 115
Girard, S. D., Baranger, K., Gauthier, C., Jacquet, M., Bernard, A., Escoffier, G., Marchetti, E., Khrestchatisky, M., Rivera, S., & Roman, F. S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120982 · Cited by 107
Serotonin, neural markers, and memory
Meneses, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00143 · Cited by 90
“Fluoxetine plus METH prevented amnesia, which was associated to DAT, EACC1 and GAT1 (prefrontal cortex), SERT and DAT (hippocampus) and EACC1 or DAT (striatal) up-regulation.”
BackgroundMethodInfluentialDifferentiation renders susceptibility to excitotoxicity in HT22 neurons
Suo, W., He, M., Liu, J., Cheng, S., & Xing, Y. (2013) · Neural Regeneration Research · doi:10.4103/1673-5374.121636 · Cited by 83
Dysregulation of synaptic and extrasynaptic N-methyl-D-aspartate receptors induced by amyloid-β
Wang, Z.-C., Zhao, J., & Li, S. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1383-2 · Cited by 54
Ceftriaxone Protects Astrocytes from MPP+ via Suppression of NF-ΚB/JNK/c-Jun Signaling
Zhang, Y., Zhang, X., & Qu, S. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8845-z · Cited by 39
Astrocytic transporters in Alzheimer's disease
Ugbode, C., Hu, Y., Whalley, B., Peers, C., Rattray, M., & Dallas, M. L. (2017) · Biochemical Journal · doi:10.1042/bcj20160505 · Cited by 25
Metadata
- Authors
- Chen, K. H., Reese, E. A., Kim, H.-W., Rapoport, S. I., & Rao, J. S.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2011-10
- Volume
- 26
- Issue
- 4
- Pages
- 755-766
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2148272634
- Cited by
- 122
- References
- 14
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.